We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Study Will Try to Prevent Asthma in Children

By HospiMedica staff writers
Posted on 18 Sep 2001
Six U.S. More...
medical centers will take part in a major two-year study that will attempt to prevent asthma in children at high risk for the disease. By treating airway inflammation at the earliest stages, researchers hope to prevent the permanent airway changes that lead to chronic asthma. The name of the study is PEAK (Prevention of Early Asthma in Kids).

In the study, researchers will enroll children of two to four years old who have had wheezing episodes in the previous year and who have one additional risk factor, such as eczema, allergies, or a parent with asthma. The children will be treated with the inhaled steroid fluticasone or an inactive inhaler as placebo twice daily for two years. Afterward, the children will be observed for one year to see if they develop asthma symptoms.

About 75% of asthmatics first develop the disease in childhood. The cause is unknown. Scientists believe a genetic predisposition coupled with environmental exposures first causes inflammation, which then progresses into chronic asthma. Steroids have been shown to be a safe, effective treatment for asthma symptoms in children as young as one year of age. Studies in older children, however, show that steroids seem to have little effect on the natural course of the disease, so that asthma symptoms return when steroids are discontinued. Other studies have suggested that irreversible changes in the airways occur in the very early stages and establish the long-term course of the disease. The PEAK researchers will try to prevent these irreversible changes.

"It is much easier to stop a small snowball that has been rolling for a few inches than it is to stop a much larger one that has been rolling for 100 yards,” said Joseph Spahn, M.D., co-investigator at National Jewish Medical and Research Center (Denver, CO, USA), one of the participating medical centers. "By treating the earliest stages of inflammation, we hope to stop the snowball of asthma before it gets a chance to gain momentum.”




Related Links:
National Jewish Medical Center

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.